abstract |
The present invention provides methods and compositions provided for determining whether a cancer is resistant to treatment with an anti-mitotic agent, including treatment with T-DM1. In a method for determining whether a patient's cancer is resistant to treatment with an anti-mitotic agent, detecting whether the ABCC3 gene is amplified in a test cancer sample from the patient. Wherein ABCC3 gene amplification indicates that the cancer is resistant to treatment with a mitotic agent. [Selection] Figure 7 |